Trifluridine adverse reactions: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Trifluridine}} {{CMG}} ==Adverse Reactions== The most frequent adverse reactions reported during controlled clinical trials were mild, transient burning or stingi..." |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Trifluridine}} | {{Trifluridine}} | ||
{{CMG}} | {{CMG}}; {{AE}} {{SS}} | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
| Line 12: | Line 12: | ||
{{FDA}} | {{FDA}} | ||
[[Category: | [[Category:Antibiotics]] | ||
[[Category:Wikinfect]] | [[Category:Wikinfect]] | ||
Revision as of 21:58, 2 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Adverse Reactions
The most frequent adverse reactions reported during controlled clinical trials were mild, transient burning or stinging upon instillation (4.6%) and palpebral edema (2.8%). Other adverse reactions in decreasing order of reported frequency were superficial punctate keratopathy, epithelial keratopathy, hypersensitivity reaction, stromal edema, irritation, keratitis sicca, hyperemia, and increased intraocular pressure.[1]
References
- ↑ "http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022211s000_sumr.pdf" (PDF). External link in
|title=(help)
Adapted from the FDA Package Insert.